NCT00452127View on ClinicalTrials.gov

A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

May 31, 2009

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

PRO131921

Escalating doses by IV infusion

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY